{"id":789631,"date":"2026-02-09T17:03:02","date_gmt":"2026-02-09T17:03:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=789631"},"modified":"2026-02-09T17:03:02","modified_gmt":"2026-02-09T17:03:02","slug":"severe-asthma-clinical-trial-analysis-indepth-analysis-of-50-novel-therapies-being-advanced-by-40-companies-reports-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/severe-asthma-clinical-trial-analysis-indepth-analysis-of-50-novel-therapies-being-advanced-by-40-companies-reports-delveinsight_789631.html","title":{"rendered":"Severe Asthma Clinical Trial Analysis: In-Depth Analysis of 50+ Novel Therapies Being Advanced by 40+ Companies, Reports DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/upload\/2026\/02\/1770618536.jpg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Severe Asthma Clinical Trial Analysis: In-Depth Analysis of 50+ Novel Therapies Being Advanced by 40+ Companies, Reports DelveInsight\" src=\"https:\/\/www.abnewswire.com\/upload\/2026\/02\/1770618536.jpg\" alt=\"Severe Asthma Clinical Trial Analysis: In-Depth Analysis of 50+ Novel Therapies Being Advanced by 40+ Companies, Reports DelveInsight\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Severe Asthma Clinical Trial<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">Prominent companies actively shaping the severe asthma treatment space include Kinaset Therapeutics, Bio-Thera Solutions, CSPC ZhongQi Pharmaceutical Technology, AB Science, GlaxoSmithKline, Oneness Biotech, Biosion, Lanier Biotherapeutics, Kymera Therapeutics, Suzhou Connect Biopharmaceuticals, Upstream Bio, Teva Branded Pharmaceutical Industries, among others.<\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s <strong>&ldquo;Severe Asthma Pipeline Insight&rdquo;<\/strong> report delivers a comprehensive assessment of the global severe asthma pipeline. The report evaluates <strong>40+ companies and 50+ pipeline therapies<\/strong>, offering extensive commercial and clinical insights across development stages ranging from discovery and preclinical research to late-stage and marketed products.<\/p>\n<p style=\"text-align: justify;\">It includes detailed drug-level intelligence covering <strong>mechanisms of action, clinical trial outcomes, regulatory progress such as NDA filings or approvals, and strategic development activities<\/strong>, including technology platforms, collaborations, mergers and acquisitions, funding initiatives, and special regulatory designations.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><em>Gain Strategic Insights Into the Severe Asthma Treatment Landscape. <\/em><\/strong><strong><em>Explore DelveInsight&rsquo;s in-depth analysis to stay informed about evolving therapeutic trends in severe asthma. Click here to learn more @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/severe-asthma-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\">Severe Asthma Pipeline Outlook<\/a><\/em><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key Highlights from the Severe Asthma Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Depemokimab (GSK)<\/strong>, a long-acting anti&ndash;IL-5 monoclonal antibody for severe type 2 inflammatory asthma, has been accepted for FDA review, with a regulatory decision anticipated by <strong>December 16, 2025<\/strong>.<\/li>\n<li><strong>In October 2025, <\/strong>Chiesi USA, Inc. (key-A-zee), a biopharmaceutical company that supports patients in living their best possible lives through life-changing or lifesaving innovations, today announced that the U.S. Food and Drug Administration has accepted the company&rsquo;s New Drug Application (NDA) for its investigational maintenance treatment of asthma in adults. Chiesi&rsquo;s inhaler delivers three active ingredients in a single device, referred to as a single inhaler triple therapy (SITT). Already approved in nearly 50 countries, this product is marketed outside of the U.S. under the brand name TRIMBOW&reg;.<\/li>\n<li>In <strong>March 2025<\/strong>, <strong>AstraZeneca<\/strong> initiated a study to assess whether adolescents and adults receiving subcutaneous <strong>tezepelumab<\/strong> can safely reduce maintenance therapy while sustaining asthma control.<\/li>\n<li><strong>Upstream Bio Inc.<\/strong> launched a clinical trial in <strong>March 2025<\/strong> evaluating <strong>verekitug (UPB-101)<\/strong> for safety and efficacy in severe asthma, focusing on exacerbation frequency, lung function, asthma control, and tolerability versus placebo.<\/li>\n<li>In <strong>January 2025<\/strong>, AstraZeneca commenced a multicenter, randomized, open-label <strong>Phase IIIb trial<\/strong> to determine if patients treated with tezepelumab can taper maintenance therapy by Week 56 and achieve remission-like outcomes by Week 24.<\/li>\n<li>Also in <strong>January 2025<\/strong>, Upstream Bio initiated an additional study of <strong>verekitug (UPB-101)<\/strong> to further examine its pharmacodynamics, efficacy, safety, and tolerability in severe asthma patients.<\/li>\n<li><strong>Incyte Corporation<\/strong> began a <strong>Phase II, double-blind, placebo-controlled, dose-ranging study<\/strong> in January 2025 to evaluate <strong>povorcitinib<\/strong> and its effects on pulmonary function in individuals with inadequately controlled moderate-to-severe asthma.<\/li>\n<li>DelveInsight reports that the severe asthma pipeline remains highly dynamic, with <strong>40+ companies collectively advancing more than 50 investigational therapies<\/strong>.<\/li>\n<li>Major players include <strong>Kinaset Therapeutics, Bio-Thera Solutions, CSPC ZhongQi Pharmaceutical Technology, AB Science, GlaxoSmithKline, Oneness Biotech, Biosion, Lanier Biotherapeutics, Kymera Therapeutics, Suzhou Connect Biopharmaceuticals, Upstream Bio, Teva<\/strong>, and others.<\/li>\n<li>Prominent pipeline candidates include <strong>Verekitug (UPB-101), FB704A, TQC2731, Benralizumab, Povorcitinib, CM326<\/strong>, among several others.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><em>Stay Updated on Breakthroughs in Severe Asthma Care. <\/em><\/strong><strong><em>Access the latest insights into clinical trials and emerging therapies by downloading DelveInsight&rsquo;s <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/severe-asthma-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\">Severe Asthma Clinical Trials Assessment<\/a><\/em><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Emerging Drugs in the Severe Asthma Pipeline<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>GSK3511294 (Depemokimab) &ndash; GlaxoSmithKline<\/strong><\/p>\n<p style=\"text-align: justify;\">Depemokimab is a long-acting monoclonal antibody targeting the <strong>interleukin-5 (IL-5) receptor<\/strong>, engineered for prolonged half-life and enhanced binding affinity compared with earlier IL-5 inhibitors. Developed by GlaxoSmithKline, the therapy is currently undergoing <strong>Phase III clinical evaluation<\/strong> for severe asthma management.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>BSI-045B &ndash; Biosion<\/strong><\/p>\n<p style=\"text-align: justify;\">BSI-045B is a humanized, high-affinity monoclonal antibody targeting <strong>thymic stromal lymphopoietin (TSLP)<\/strong>, a cytokine implicated in asthma and other Th2-mediated inflammatory diseases. Biosion&rsquo;s partner <strong>CTTQ<\/strong>, which holds development and commercialization rights in China, is conducting a <strong>Phase II clinical trial<\/strong> of <strong>TQC2731<\/strong> in patients with severe uncontrolled asthma.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Mepolizumab &ndash; Bio-Thera Solutions<\/strong><\/p>\n<p style=\"text-align: justify;\">Mepolizumab is a subcutaneously administered <strong>IL-5 antagonist monoclonal antibody<\/strong>, delivered via syringe or autoinjector. It is approved as an add-on maintenance therapy for several eosinophilic conditions, including severe eosinophilic asthma, chronic rhinosinusitis with nasal polyps, EGPA, and hypereosinophilic syndrome. Bio-Thera Solutions is currently evaluating mepolizumab in a <strong>Phase I study<\/strong> for severe asthma.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><em>Discover Transformative Therapies in the Severe Asthma Pipeline. <\/em><\/strong><strong><em>Access DelveInsight&rsquo;s detailed report to explore emerging drugs and active clinical programs @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/severe-asthma-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\">Severe Asthma Treatment Drugs<\/a><\/em><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Severe Asthma Companies Profiled<\/strong><\/p>\n<p style=\"text-align: justify;\">Key companies featured in the report include <strong>Kinaset Therapeutics, Bio-Thera Solutions, CSPC ZhongQi Pharmaceutical Technology, AB Science, GlaxoSmithKline, Oneness Biotech, Biosion, Lanier Biotherapeutics, Kymera Therapeutics, Suzhou Connect Biopharmaceuticals, Upstream Bio, Teva Branded Pharmaceutical Industries<\/strong>, and others.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Route of Administration Analysis<\/strong><\/p>\n<p style=\"text-align: justify;\">The severe asthma pipeline therapies are evaluated across multiple routes of administration, including:<\/p>\n<ul style=\"text-align: justify;\">\n<li>Oral<\/li>\n<li>Intravenous<\/li>\n<li>Subcutaneous<\/li>\n<li>Parenteral<\/li>\n<li>Topical<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Molecule Type Classification<\/strong><\/p>\n<p style=\"text-align: justify;\">Pipeline products are categorized based on molecular modality, such as:<\/p>\n<ul style=\"text-align: justify;\">\n<li>Recombinant fusion proteins<\/li>\n<li>Small molecules<\/li>\n<li>Monoclonal antibodies<\/li>\n<li>Peptides<\/li>\n<li>Polymers<\/li>\n<li>Gene therapies<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><em>Understanding the Future of Severe Asthma Treatment. <\/em><\/strong><strong><em>DelveInsight&rsquo;s expert analysis sheds light on upcoming therapies, pipeline trends, and key players shaping the severe asthma market @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/severe-asthma-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\">Severe Asthma Market Drivers and Barriers<\/a><\/em><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Severe Asthma Market Drivers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Rising Disease Prevalence:<\/strong> Increasing cases of eosinophilic and uncontrolled asthma are expanding the addressable patient population.<\/li>\n<li><strong>Growing Use of Biologics:<\/strong> Advances in biologics targeting IL-5, IL-4\/13, IgE, and TSLP are transforming disease management and reducing exacerbations.<\/li>\n<li><strong>Improved Diagnostic Tools:<\/strong> Greater adoption of biomarkers, phenotyping, and precision medicine approaches is enhancing treatment selection.<\/li>\n<li><strong>Increased Awareness and Access:<\/strong> Better physician education, patient awareness, and access to specialty centers are improving diagnosis and care.<\/li>\n<li><strong>Supportive Reimbursement Policies:<\/strong> Favorable coverage in developed markets such as the US and EU is accelerating uptake of high-cost biologics.<\/li>\n<li><strong>Robust R&amp;D Activity:<\/strong> Strong pipeline momentum driven by innovation in long-acting biologics and next-generation anti-inflammatory targets.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Severe Asthma Market Challenges<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>High Cost of Biologic Treatments:<\/strong> Premium pricing limits affordability and reimbursement in many regions.<\/li>\n<li><strong>Diagnostic Complexity:<\/strong> Identifying specific asthma phenotypes requires advanced testing infrastructure.<\/li>\n<li><strong>Adherence Barriers:<\/strong> Long-term treatment regimens and injectable therapies can affect patient compliance.<\/li>\n<li><strong>Limited Penetration in Emerging Markets:<\/strong> Infrastructure gaps and financial constraints hinder adoption.<\/li>\n<li><strong>Safety and Long-Term Risk Concerns:<\/strong> Potential adverse effects and limited long-term data may slow uptake.<\/li>\n<li><strong>Regulatory and Access Hurdles:<\/strong> Prolonged approval timelines can delay market entry.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Severe Asthma Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Geographic Coverage:<\/strong> Global<\/li>\n<li><strong>Key Companies:<\/strong> Kinaset Therapeutics, Bio-Thera Solutions, CSPC ZhongQi Pharmaceutical Technology, AB Science, GlaxoSmithKline, Oneness Biotech, Biosion, Lanier Biotherapeutics, Kymera Therapeutics, Suzhou Connect Biopharmaceuticals, Upstream Bio, Teva, and others<\/li>\n<li><strong>Key Therapies:<\/strong> Verekitug (UPB-101), FB704A, TQC2731, Benralizumab, Povorcitinib, CM326, and others<\/li>\n<li><strong>Therapeutic Assessment:<\/strong> Mono, combination, and mono\/combination therapies<\/li>\n<li><strong>Development Stages Covered:<\/strong> Discovery, Preclinical, Phase I, Phase II, Phase III<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><em>Get the Latest Insights on Severe Asthma Therapies. <\/em><\/strong><strong><em>Download DelveInsight&rsquo;s comprehensive pipeline report to explore key products, companies, and unmet needs @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/severe-asthma-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\">Severe Asthma Companies, Key Products and Unmet Needs<\/a><\/em><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Introduction<\/li>\n<li>Executive Summary<\/li>\n<li>Severe Asthma Overview<\/li>\n<li>Pipeline Therapeutics<\/li>\n<li>Therapeutic Assessment<\/li>\n<li>DelveInsight&rsquo;s Analytical Perspective<\/li>\n<li>Late-Stage Products (Phase III)<\/li>\n<li>Mid-Stage Products (Phase II)<\/li>\n<li>Early-Stage Products (Phase I)<\/li>\n<li>Preclinical &amp; Discovery Programs<\/li>\n<li>Inactive Products<\/li>\n<li>Key Companies &amp; Products<\/li>\n<li>Unmet Needs<\/li>\n<li>Market Drivers &amp; Barriers<\/li>\n<li>Future Outlook &amp; Conclusion<\/li>\n<li>Analyst Views<\/li>\n<li>Appendix<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading life sciences&ndash;focused market research and consulting firm providing high-quality intelligence and strategic insights to pharmaceutical and healthcare organizations worldwide. With deep industry expertise and customized research solutions, DelveInsight supports informed decision-making and helps clients stay ahead in an evolving healthcare landscape.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=severe-asthma-clinical-trial-analysis-indepth-analysis-of-50-novel-therapies-being-advanced-by-40-companies-reports-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +14699457679<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\/competitive-intelligence-services\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting\/competitive-intelligence-services<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=severe-asthma-clinical-trial-analysis-indepth-analysis-of-50-novel-therapies-being-advanced-by-40-companies-reports-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Severe Asthma Clinical Trial Prominent companies actively shaping the severe asthma treatment space include Kinaset Therapeutics, Bio-Thera Solutions, CSPC ZhongQi Pharmaceutical Technology, AB Science, GlaxoSmithKline, Oneness Biotech, Biosion, Lanier Biotherapeutics, Kymera Therapeutics, Suzhou Connect Biopharmaceuticals, Upstream Bio, Teva Branded Pharmaceutical &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/severe-asthma-clinical-trial-analysis-indepth-analysis-of-50-novel-therapies-being-advanced-by-40-companies-reports-delveinsight_789631.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,413],"tags":[],"class_list":["post-789631","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/789631","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=789631"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/789631\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=789631"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=789631"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=789631"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}